Cargando…

A perspective to weaponize microRNAs against lung cancer

microRNAs are regulatory RNAs that silence specific mRNA by binding to it, inducing translational repression. Over the recent decades since the discovery of RNA interference, the field of microRNA therapeutics has expanded tremendously. The role of miRNAs in disease development has attracted researc...

Descripción completa

Detalles Bibliográficos
Autores principales: Murugan, Dhanashree, Rangasamy, Loganathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556932/
https://www.ncbi.nlm.nih.gov/pubmed/36262424
http://dx.doi.org/10.1016/j.ncrna.2022.09.009
_version_ 1784807186381144064
author Murugan, Dhanashree
Rangasamy, Loganathan
author_facet Murugan, Dhanashree
Rangasamy, Loganathan
author_sort Murugan, Dhanashree
collection PubMed
description microRNAs are regulatory RNAs that silence specific mRNA by binding to it, inducing translational repression. Over the recent decades since the discovery of RNA interference, the field of microRNA therapeutics has expanded tremendously. The role of miRNAs in disease development has attracted researchers to investigate their potential in therapeutics. In lung cancer, multiple miRNAs are deregulated, and their involvement is observed in cell proliferation, immunomodulation, angiogenesis, and epithelial-mesenchymal transition. Thus, synthetic oligonucleotides are developed to downregulate the overexpressed miRNA or to upregulate the repressed miRNA. However, their clinical efficiency is limited due to the requirement for an effective delivery strategy. Advances in the current understanding of nanotechnology, biomaterial science, and disease molecular pathology have increased the chances of overcoming the limitations of miRNA-based therapy. This review enlists downregulated and upregulated miRNAs in lung cancer. This review also highlights the major contributions to miRNA-based therapeutics for lung cancer and strategies to overcome endosomal barriers. It also attempts to understand the nuances between current advancements in delivery methods, advantages, disadvantages, and practical issues for the large-scale development of miRNA-based therapeutics.
format Online
Article
Text
id pubmed-9556932
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-95569322022-10-18 A perspective to weaponize microRNAs against lung cancer Murugan, Dhanashree Rangasamy, Loganathan Noncoding RNA Res Review Article microRNAs are regulatory RNAs that silence specific mRNA by binding to it, inducing translational repression. Over the recent decades since the discovery of RNA interference, the field of microRNA therapeutics has expanded tremendously. The role of miRNAs in disease development has attracted researchers to investigate their potential in therapeutics. In lung cancer, multiple miRNAs are deregulated, and their involvement is observed in cell proliferation, immunomodulation, angiogenesis, and epithelial-mesenchymal transition. Thus, synthetic oligonucleotides are developed to downregulate the overexpressed miRNA or to upregulate the repressed miRNA. However, their clinical efficiency is limited due to the requirement for an effective delivery strategy. Advances in the current understanding of nanotechnology, biomaterial science, and disease molecular pathology have increased the chances of overcoming the limitations of miRNA-based therapy. This review enlists downregulated and upregulated miRNAs in lung cancer. This review also highlights the major contributions to miRNA-based therapeutics for lung cancer and strategies to overcome endosomal barriers. It also attempts to understand the nuances between current advancements in delivery methods, advantages, disadvantages, and practical issues for the large-scale development of miRNA-based therapeutics. KeAi Publishing 2022-09-29 /pmc/articles/PMC9556932/ /pubmed/36262424 http://dx.doi.org/10.1016/j.ncrna.2022.09.009 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Murugan, Dhanashree
Rangasamy, Loganathan
A perspective to weaponize microRNAs against lung cancer
title A perspective to weaponize microRNAs against lung cancer
title_full A perspective to weaponize microRNAs against lung cancer
title_fullStr A perspective to weaponize microRNAs against lung cancer
title_full_unstemmed A perspective to weaponize microRNAs against lung cancer
title_short A perspective to weaponize microRNAs against lung cancer
title_sort perspective to weaponize micrornas against lung cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556932/
https://www.ncbi.nlm.nih.gov/pubmed/36262424
http://dx.doi.org/10.1016/j.ncrna.2022.09.009
work_keys_str_mv AT murugandhanashree aperspectivetoweaponizemicrornasagainstlungcancer
AT rangasamyloganathan aperspectivetoweaponizemicrornasagainstlungcancer
AT murugandhanashree perspectivetoweaponizemicrornasagainstlungcancer
AT rangasamyloganathan perspectivetoweaponizemicrornasagainstlungcancer